SCPS:OTC-Scopus Biopharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0001

Change

0.00 (0.00)%

Market Cap

USD 0.01M

Volume

318.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

-3.59 (-3.92%)

USD 34.50B
UCBJF UCB SA

N/A

USD 34.08B
ARGNF argenx SE

N/A

USD 32.00B
GNMSF Genmab A/S

-1.32 (-0.51%)

USD 17.00B
ZLDPF Zealand Pharma A/S

N/A

USD 9.86B
IVBIY IVBIY

N/A

USD 8.92B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.29B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.27B
AKESF Akeso, Inc.

-0.10 (-1.06%)

USD 7.07B
WXIBF WuXi Biologics

N/A

USD 6.08B

ETFs Containing SCPS

IGE 1,000.00 % 0.46 %

N/A

N/A
WTID UBS ETRACS - ProShares Da.. 11.60 % 0.00 %

-0.94 (0%)

USD 5.15M
WTIU UBS ETRACS - ProShares Da.. 11.60 % 0.00 %

+0.62 (+0%)

USD 8.63M
IOGP:LSE iShares Oil & Gas Explora.. 10.25 % 0.00 %

+0.50 (+0%)

N/A
SPOG:LSE iShares V Public Limited .. 10.25 % 0.00 %

+42.25 (+0%)

N/A
NRGO 10.00 % 0.00 %

N/A

N/A
NRGZ 10.00 % 0.00 %

N/A

N/A
YGRN 10.00 % 0.00 %

N/A

N/A
IS0D:F iShares Oil & Gas Explora.. 9.84 % 0.00 %

N/A

N/A
FRAK 8.73 % 0.54 %

N/A

N/A
IESU:LSE iShares S&P 500 Energy Se.. 7.90 % 0.00 %

+12.25 (+0%)

N/A
QDVF:F iShares S&P 500 Energy Se.. 7.81 % 0.00 %

+0.13 (+0%)

N/A
FTXN First Trust Nasdaq Oil & .. 7.79 % 0.60 %

+0.44 (+0%)

USD 0.17B
JHME 6.90 % 0.48 %

N/A

N/A
DDG 5.83 % 0.95 %

N/A

N/A
DUG ProShares UltraShort Oil .. 5.83 % 0.95 %

-0.29 (0%)

N/A
ERYY 4.79 % 0.45 %

N/A

N/A
WNRG:LSE SPDR MSCI World Energy UC.. 4.71 % 0.00 %

+0.73 (+0%)

N/A
FCG First Trust Natural Gas E.. 4.55 % 0.60 %

+0.38 (+0%)

N/A
XDW0:LSE db x-trackers MSCI World .. 4.53 % 0.00 %

+0.67 (+0%)

N/A
SXLE:LSE SPDR S&P U.S. Energy Sele.. 4.49 % 0.00 %

+0.56 (+0%)

N/A
HUL-U:CA 4.46 % 0.00 %

N/A

N/A
HUL:CA 4.46 % 2.20 %

N/A

N/A
NANR SPDR S&P® North American.. 4.30 % 0.35 %

+0.37 (+0%)

N/A
GASX 4.29 % 1.01 %

N/A

N/A
DIG ProShares Ultra Oil & Gas 3.29 % 0.95 %

+1.06 (+0%)

N/A
XOP SPDR® S&P Oil & Gas Expl.. 3.03 % 0.35 %

+2.33 (+0%)

N/A
ERX Direxion Daily Energy Bul.. 3.00 % 1.08 %

+1.55 (+0%)

N/A
SPGP Invesco S&P 500 GARP ETF 2.04 % 0.36 %

+1.05 (+0%)

USD 4.33B
GASL 1.45 % 1.19 %

N/A

N/A
TERM 0.88 % 0.64 %

N/A

N/A
SCHJ Schwab 1-5 Year Corporate.. 0.09 % 0.00 %

-0.01 (0%)

N/A
BWX SPDR® Bloomberg Internat.. 0.00 % 0.50 %

-0.07 (0%)

N/A
EBND SPDR® Bloomberg Emerging.. 0.00 % 0.41 %

N/A

N/A
ILF iShares Latin America 40 .. 0.00 % 0.48 %

+0.03 (+0%)

N/A
MTUM 0.00 % 0.15 %

N/A

N/A
RYE 0.00 % 0.40 %

N/A

N/A
WIP SPDR® FTSE International.. 0.00 % 0.50 %

-0.14 (0%)

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

+5.14 (+0%)

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

+1.30 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.77% 3% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.77% 2% F 1% F
Trailing 12 Months  
Capital Gain -99.77% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.77% 2% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -65.93% 1% F N/A F
Dividend Return -65.93% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.68% 73% C 58% F
Risk Adjusted Return -162.10% 2% F N/A F
Market Capitalization 0.01M 9% A- 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.